Effect of Rituximab Timing on COVID-19-Related Death in ANCA-Associated Vasculitis
Treatment with rituximab and immunoglobulin levels may increase risk for COVID-19-related death in ANCA-associated vasculitis.
Treatment with rituximab and immunoglobulin levels may increase risk for COVID-19-related death in ANCA-associated vasculitis.
Researchers estimated cardiovascular risk by different strategies in patients with RA; analyzed the percentage of patients who would be candidates to receive statin therapy; and identified how many patients met the recommended lipid goals.
Patients with systemic lupus erythematosus have a higher risk for cardiovascular events and mortality.
Patients with rheumatoid arthritis are at increased risk for ischemic and non-ischemic heart disease.
Among patients with rheumatoid arthritis treated with DMARDs, cardiovascular risk associated with abatacept and TNF-α inhibitors is lower compared with conventional synthetic DMARDs.
The objective of this study was to determine the impact of KME on postprandial glucose, systemic inflammation, and vascular function in adults with obesity.
Immigrants may be at a lower risk for mortality after ischemic stroke compared with long-term residents, but the risk for vascular event recurrence was similar in both populations.
The C-reactive protein to albumin ratio is a novel inflammation marker that may be a valuable predictor of coronary artery lesion formation in Kawasaki disease.
For inpatients with ischemic heart disease, redesign of decision pathways from default opt-in to opt-out of CR results in a significant increase in CR referrals.
Researchers evaluated the combined use of the European SCORE and QRISK3 algorithms as predictors of carotid plaques in patients with rheumatoid arthritis.